speb/financial-data huggingface dataset:
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 469520000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Minority Interests: -36460000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 0.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: -820000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Income: 1333050000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 1333050000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 1369510000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 1333050000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 1333050000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 1878210000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 1369510000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Intangibles Purchase And Sale: -500000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Interest Income: 92050000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -304300000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: 120550000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -6480000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 92050000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Other Financing Charges: -56070000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Net PPE: 3072650000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -421580000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Net Short Term Debt Issuance: 127030000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 9405470000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 142820000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 343240000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 8860000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 80230000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 2349100000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Normalized Income: 1398083514.30
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 1413690000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Operating Income: 1728280000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Operating Revenue: 6234770000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 111824075.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 17260000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 135910000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 30310000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 582860000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: 49800000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 300000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 141580000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 793590000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Payable: 274020000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Properties: 2765280000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 14200000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 4342210000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Other Special Charges: 154370000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Payables: 524610000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 111040000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Pretax Income: 1878210000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: -45620000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Purchase Of Intangibles: -500000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -304300000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -423130000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 763270000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 1594110000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 352420000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 79530000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 79530000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -6480000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Research And Development: 8120000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 2260000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 10794910000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 1550000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 156510000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 397220000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Share Issued: 111824075.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Short Term Debt Issuance: 127030000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Special Income Charges: -175320000.00
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 30310000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 13241280000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 9405470000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: -24156485.70
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Tax Provision: 508700000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.27
ADVENZYMES.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -492340000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Assets: 15354630000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 13310880000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Debt: 473080000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 13710800000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Total Expenses: 4506490000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 1643830000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 7259920000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 580260000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Total Other Finance Cost: 11930000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 91410000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Total Unusual Items: -89190000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: -89190000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Treasury Shares Number: 0.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Work In Process: 363410000.00
ADVENZYMES.NS balance_sheet (annual, 2024-03-31) — Working Capital: 7031140000.00
ADVENZYMES.NS income_statement (annual, 2024-03-31) — Write Off: 20950000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 225260000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 987580000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 45200000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 212290000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 223650000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 977830000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 5224560000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 223650000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 13416540000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 338780000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 8053930000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 65390000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 190070000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 255460000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 1039520000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 186090000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 3277510000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 3841180000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 3150280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 1684100000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 13673430000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 45200000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 146900000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 66820000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 213720000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 11440000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 471310000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 3150280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 9575360000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 130790000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 339280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 111824075.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 156480000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 145110000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 13192890000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 563670000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 28840000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 2811500000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 1210000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 4246730000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Payables: 231120000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 111824075.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 13416540000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 9575360000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 15491810000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 13483360000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 469180000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 13887850000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 1603960000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 7437880000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 564440000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 5860000.00
ADVENZYMES.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 7014410000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — +Operating Expense: 3110860000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 855660000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — +Total Revenue: 6365070000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 1671790000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 194820000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 194820000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 1153990000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 1153990000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -2151450000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -2151450000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 840220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 840220000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -21220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -21220000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Amortization: 75610000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 75610000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 55600000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 55600000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 111852146.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 111738397.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Basic EPS: 11.72
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 2.37
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 1137510000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 1535460000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 1535460000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -347810000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Capital Expenditure Reported: 0.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 178140000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 178140000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 223760000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 223760000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 942250000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 942250000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 5950540000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 5950540000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -590300000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 675150000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 675150000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 267100000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 267100000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -77970000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: 133680000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -45610000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Change In Payable: 34870000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -177750000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -122300000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Changes In Cash: -191480000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Common Stock: 223760000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 223760000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 14208630000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 14208630000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 3780000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 216910000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 216910000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 1648420000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 460870000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Current Assets: 8798690000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 8798690000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 60800000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 60800000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Current Debt: 123530000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 123530000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 184330000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 184330000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 962470000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 962470000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 208600000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 208600000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Depreciation: 289950000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 365560000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 365560000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 100760000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 289950000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 100760000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 111990345.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 111738397.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Diluted EPS: 11.71
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 2.37
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 1311150000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 264820000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 2280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 2280000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — EBIT: 1909210000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — EBIT: 442710000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — EBITDA: 2274770000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — EBITDA: 543470000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Effect Of Exchange Rate Changes: -3780000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — End Cash Position: 942250000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 650000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 650000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: -725440000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 382860000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 382860000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: 1077160000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -82250000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -2170000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 208920000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Goodwill: 3334400000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 3334400000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 3857480000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 3857480000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 1175210000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 1175210000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 5297780000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 5297780000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Gross Profit: 4716650000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 1210920000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 0.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Interest Expense: 35570000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 8110000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 35570000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 8110000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Interest Income: 198060000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 198060000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -33420000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 99430000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Inventory: 1573050000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 1573050000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 14423990000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 14423990000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -891010000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 56250000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 56250000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 3780000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 22300000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 587050000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 587050000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 117340000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 117340000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 91830000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 91830000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 209170000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 209170000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 22300000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 13710000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 13710000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 2958360000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 2958360000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 478070000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 478070000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Minority Interests: -28590000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Minority Interests: -2460000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 3780000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: -840000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Income: 1311150000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Income: 264820000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 1311150000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 264820000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 1339740000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 267280000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 1311150000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 264820000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 1311150000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 264820000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 1873640000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 1339740000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 267280000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Intangibles Purchase And Sale: -9730000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Interest Income: 151730000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -8110000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: -647900000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -35780000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: 22300000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 151730000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -8110000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Net PPE: 3146330000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 3146330000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net PPE Purchase And Sale: -332810000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Net Short Term Debt Issuance: -58080000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Net Tangible Assets: 10351150000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 10351150000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Assets: 101920000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Assets: 101920000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Non Current Deferred Taxes Liabilities: 336340000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 336340000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 18790000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Non Current Pension And Other Postretirement Benefit Plans: 18790000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Non Current Prepaid Assets: 74170000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Non Current Prepaid Assets: 74170000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Normalized EBITDA: 2229310000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 543470000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Normalized Income: 1278643979.42
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Normalized Income: 264820000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Operating Cash Flow: 1424970000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Operating Income: 1605790000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Operating Income: 355260000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Operating Revenue: 6365070000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Operating Revenue: 1671790000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Ordinary Shares Number: 111881150.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 111881150.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Current Assets: 13740000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 13740000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Current Liabilities: 85280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 85280000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Equity Interest: 49530000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Equity Interest: 49530000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Intangible Assets: 523080000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 523080000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Other Non Cash Items: -60800000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Non Current Assets: 300000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 300000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Other Non Operating Income Expenses: 60910000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 87450000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Other Operating Expenses: 815220000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Other Operating Expenses: 386530000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Payable: 254550000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Payable: 254550000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Properties: 2929410000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Properties: 2929410000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Receivables: 8120000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Receivables: 8120000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Other Short Term Investments: 5008290000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 5008290000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Other Special Charges: -2290000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Payables: 497570000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Payables: 497570000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Prepaid Assets: 96970000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 96970000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Pretax Income: 1873640000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Pretax Income: 434600000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Properties: 0.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Properties: 0.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Provisionand Write Offof Assets: 9980000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Purchase Of Intangibles: -9730000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Purchase Of Investment: -647900000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Purchase Of PPE: -338080000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Raw Materials: 753990000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Raw Materials: 753990000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Reconciled Cost Of Revenue: 1648420000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 460870000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Reconciled Depreciation: 365560000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 100760000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Rent And Landing Fees: 77790000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Rent Expense Supplemental: 77790000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Repayment Of Debt: -58080000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Research And Development: 8750000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Restricted Cash: 2280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Restricted Cash: 2280000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Retained Earnings: 11530790000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 11530790000.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Sale Of PPE: 5270000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Selling And Marketing Expense: 217170000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Selling General And Administration: 426090000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Share Issued: 111881150.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Share Issued: 111881150.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Short Term Debt Payments: -58080000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Special Income Charges: -13550000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Special Income Charges: 0.00
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Stock Based Compensation: 34460000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Stockholders Equity: 14208630000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 14208630000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Tangible Book Value: 10351150000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 10351150000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Tax Effect Of Unusual Items: 12953979.42
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Tax Provision: 533900000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Tax Provision: 167320000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Tax Rate For Calcs: 0.28
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.38
ADVENZYMES.NS cash_flow (annual, 2025-03-31) — Taxes Refund Paid: -596740000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Assets: 16213470000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Assets: 16213470000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Capitalization: 14300460000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 14300460000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Debt: 393500000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Debt: 393500000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Equity Gross Minority Interest: 14686700000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 14686700000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Total Expenses: 4759280000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Total Expenses: 1316530000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Liabilities Net Minority Interest: 1526770000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 1526770000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Non Current Assets: 7414790000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 7414790000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 564300000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 564300000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Total Other Finance Cost: 10760000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Total Tax Payable: 45920000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 45920000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Total Unusual Items: 45460000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items: 0.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Total Unusual Items Excluding Goodwill: 45460000.00
ADVENZYMES.NS income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 0.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Work In Process: 436200000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Work In Process: 436200000.00
ADVENZYMES.NS balance_sheet (annual, 2025-03-31) — Working Capital: 7836220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-03-31) — Working Capital: 7836220000.00
ADVENZYMES.NS income_statement (annual, 2025-03-31) — Write Off: 15840000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — +Operating Expense: 890510000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — +Total Revenue: 1859140000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Basic Average Shares: 111848739.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Basic EPS: 3.57
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 500490000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Depreciation And Amortization In Income Statement: 96180000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Depreciation Income Statement: 96180000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 111848739.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Diluted EPS: 3.57
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 399300000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — EBIT: 556640000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — EBITDA: 652820000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Gross Profit: 1358650000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Interest Expense: 7640000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 7640000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Minority Interests: -5100000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Income: 399300000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 399300000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 404400000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 399300000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 399300000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 404400000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Interest Income: -7640000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: -7640000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 652820000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Normalized Income: 399300000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Operating Income: 468140000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Operating Revenue: 1859140000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 88500000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Other Operating Expenses: 397200000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Otherunder Preferred Stock Dividend: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Pretax Income: 549000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 500490000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 96180000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Special Income Charges: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Tax Provision: 144600000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.26
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Total Expenses: 1391000000.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 0.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — +Operating Expense: 899820000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — +Total Revenue: 1845280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 293010000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 1252770000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 42580000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Basic Average Shares: 111953488.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Basic EPS: 3.87
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 150050000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Capital Stock: 223760000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 623570000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 6190110000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Common Stock: 223760000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 14845450000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Construction In Progress: 310250000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 445670000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Current Assets: 9334600000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 77590000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Current Debt: 109600000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 187190000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 1067310000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Current Provisions: 202910000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Depreciation And Amortization In Income Statement: 100760000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Depreciation Income Statement: 100760000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Diluted Average Shares: 111953488.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Diluted EPS: 3.87
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 433260000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — EBIT: 602630000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — EBITDA: 703390000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Goodwill: 3480870000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 3985210000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Gross PPE: 3154720000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Gross Profit: 1399610000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Interest Expense: 7220000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 7220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Inventory: 1734230000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Invested Capital: 15041940000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Investmentin Financial Assets: 42580000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 72460000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 86890000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 159350000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Long Term Provisions: 18780000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Minority Interest: 490250000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Minority Interests: -14070000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Income: 433260000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 433260000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 447330000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 433260000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 433260000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 447330000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Interest Income: -7220000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: -7220000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Net PPE: 3154720000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 10860240000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Assets: 117470000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Non Current Deferred Taxes Liabilities: 337820000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Normalized EBITDA: 703390000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Normalized Income: 433260000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Operating Income: 499790000.00
ADVENZYMES.NS income_statement (quarterly, 2025-09-30) — Operating Revenue: 1845280000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 111881150.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Current Assets: 154640000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Current Liabilities: 118190000.00
ADVENZYMES.NS balance_sheet (quarterly, 2025-09-30) — Other Equity Interest: 14621690000.00